<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04278924</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-079-1004</org_study_id>
    <secondary_id>2019-004103-12</secondary_id>
    <nct_id>NCT04278924</nct_id>
  </id_info>
  <brief_title>A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Persistent/Chronic Primary Immune Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary immune thrombocytopenia (ITP) is a rare disease that results in low levels of&#xD;
      platelets - the cells that help blood clot.&#xD;
&#xD;
      The main aim of the study is to check for side effects from taking TAK-079 at three different&#xD;
      dose levels. Another aim is to learn if TAK-079 can increase the platelet count in people&#xD;
      with ITP.&#xD;
&#xD;
      In addition to receiving stable background therapy for ITP, participants will receive an&#xD;
      injection of either TAK-079 or a placebo once a week for 2 months. A placebo looks like&#xD;
      TAK-079 but will not have any medicine in it. After treatment, all participants will be&#xD;
      followed-up for another 2 months.&#xD;
&#xD;
      Then, participants who received TAK-079 will continue to be followed-up for an extra 4&#xD;
      months. Participants who received the placebo and would like to receive TAK-079 may be able&#xD;
      to do this in an extension period in the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-079. TAK-079 is being tested to treat&#xD;
      people who have primary immune thrombocytopenia (ITP). This study will evaluate the safety&#xD;
      and biologic activity of TAK-079 or matching placebo in combination with stable ITP&#xD;
      background therapy.&#xD;
&#xD;
      The study will enroll approximately 54 patients. In Part A of the study, participants will be&#xD;
      randomly assigned (by chance, like flipping a coin) to one of the three treatment groups.&#xD;
      Those who received placebo in this period will have the choice to receive study drug after a&#xD;
      safety follow-up period and will be randomized to one of the two open-label TAK-079 treatment&#xD;
      arms.&#xD;
&#xD;
      In Part B participants will be randomly assigned to one of two treatment groups. Those who&#xD;
      received placebo in this period will have the choice to receive study drug after a safety&#xD;
      follow-up period in a single open-label TAK-079 treatment arm.&#xD;
&#xD;
      This multi-center trial will be conducted worldwide. All participants will be followed for at&#xD;
      least 8 weeks in a safety follow-up period after the 8 weeks of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with At Least One Grade 3 or Higher Treatment Emergent Adverse Event (TEAE), Serious Adverse Event (SAE), and Adverse Event (AE) Leading to TAK-079 Discontinuation</measure>
    <time_frame>From the first dose of study drug up to Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Platelet Response</measure>
    <time_frame>Up to Week 16</time_frame>
    <description>Platelet response is defined as a platelet count ≥50,000/μL and ≥20,000/μL above baseline on at least 2 visits without a dosing period-permitted rescue treatment in the previous 4 weeks and without any other previous rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Complete Platelet Response</measure>
    <time_frame>Up to Week 16</time_frame>
    <description>Complete platelet response is defined as a platelet count ≥100,000/μL on at least 2 visits without a dosing period-permitted rescue treatment in the previous 4 weeks and without any other previous rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Clinically Meaningful Platelet Response</measure>
    <time_frame>Up to Week 16</time_frame>
    <description>A clinically meaningful platelet response is defined as a platelet count ≥20,000/μL above baseline on at least 2 visits without a dosing period-permitted rescue treatment in the previous 4 weeks and without any other previous rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Hemostatic Platelet Response</measure>
    <time_frame>Up to Week 16</time_frame>
    <description>A hemostatic platelet response is defined for participants with a baseline platelet count of &lt;15,000/μL who achieve a platelet count of ≥30,000/μL and ≥20,000/μL above baseline on at least 2 visits without a dosing period-permitted rescue treatment in the previous 4 weeks and without any other previous rescue therapy.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Primary Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Part A: Double Blind, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-079 placebo-matching injection subcutaneously (SC) once weekly (QW) for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Double Blind, TAK-079 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-079 Dose 1, SC injection QW for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Double Blind, TAK-079 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-079 Dose 2, SC injection QW for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Open-label Extension (OLE) Phase, TAK-079 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received placebo in double-blind Part A and opt to receive further treatment who have been randomized to receive TAK-079 Dose 1, SC injection QW for 8 weeks in OLE phase of Part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: OLE Phase, TAK-079 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received placebo in double-blind Part A and opt to receive further treatment who have been randomized to receive TAK-079 Dose 2, SC injection QW for 8 weeks in OLE phase of Part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Double Blind, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-079 placebo-matching injection SC, QW for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Double Blind, TAK-079 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-079 Dose 3, SC injection QW for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: OLE Phase, TAK-079 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received placebo in double-blind Part B and opt to receive further treatment will receive TAK-079 Dose 3, SC injection QW for 8 weeks in OLE phase of Part B.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>TAK-079 placebo-matching SC injection.</description>
    <arm_group_label>Part A: Double Blind, Placebo</arm_group_label>
    <arm_group_label>Part B: Double Blind, Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-079</intervention_name>
    <description>TAK-079 SC injection.</description>
    <arm_group_label>Part A: Double Blind, TAK-079 Dose 1</arm_group_label>
    <arm_group_label>Part A: Double Blind, TAK-079 Dose 2</arm_group_label>
    <arm_group_label>Part A: OLE Phase, TAK-079 Dose 2</arm_group_label>
    <arm_group_label>Part A: Open-label Extension (OLE) Phase, TAK-079 Dose 1</arm_group_label>
    <arm_group_label>Part B: Double Blind, TAK-079 Dose 3</arm_group_label>
    <arm_group_label>Part B: OLE Phase, TAK-079 Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with ITP that has persisted for ≥3 months, diagnosed in accordance to The&#xD;
             American Society of Hematology 2011 Evidence-based Practice Guideline for Immune&#xD;
             Thrombocytopenia or the International Consensus Report on The Investigation and&#xD;
             Management of Primary Immune Thrombocytopenia as locally applicable.&#xD;
&#xD;
          2. Has a mean platelet count of &lt;30,000/μL (and individually ≤35,000/μL) on at least 2&#xD;
             measurements at least 1 week apart during screening.&#xD;
&#xD;
          3. Diagnosis of ITP supported by a prior response to an ITP therapy (other than a&#xD;
             thrombopoietin receptor agonists [TPO-RA]) that achieved a platelet count of&#xD;
             ≥50,000/μL.&#xD;
&#xD;
          4. If receiving standard background treatment for ITP, treatment should be stable in dose&#xD;
             and frequency for at least 4 weeks before dosing.&#xD;
&#xD;
               1. Permitted standard background treatments may include: 1 oral corticosteroid; ±1&#xD;
                  immunosuppressant from the following list: azathioprine, danazol, dapsone,&#xD;
                  cyclosporine, mycophenolate mofetil, mycophenolate sodium; ±1 TPO-RA&#xD;
                  (romiplostim, eltrombopag, avatrombopag); ±fostamatinib. Corticosteroids,&#xD;
                  including dexamethasone, must be given as oral, daily or every-other-day therapy&#xD;
                  as opposed to pulse therapy.&#xD;
&#xD;
               2. The dose of any permitted standard background therapy must be expected to remain&#xD;
                  stable through the study, unless dose reduction is required because of&#xD;
                  toxicities.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of anticoagulants or any drug with antiplatelet effect (such as aspirin) within 3&#xD;
             weeks before screening.&#xD;
&#xD;
          2. Has a history of any thrombotic or embolic event within 12 months before screening.&#xD;
&#xD;
          3. Has a history of splenectomy within 3 months before screening.&#xD;
&#xD;
          4. Use of intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin or anti-D&#xD;
             immunoglobulin treatment within 4 weeks of screening, or an expectation that any&#xD;
             therapy besides the patient's standard background therapies may be used for treatment&#xD;
             of thrombocytopenia (e.g., a rescue therapy) between screening and dosing.&#xD;
&#xD;
          5. Diagnosed with chronic obstructive pulmonary disease (COPD) or asthma, and a&#xD;
             prebronchodilatory forced expiratory volume in 1 minute (FEV1) &lt;50% of predicted&#xD;
             normal.&#xD;
&#xD;
          6. Use of rituximab or any monoclonal antibody (mAb) for immunomodulation within 4 months&#xD;
             before first dosing. Note: Participants with prior exposure to rituximab must have&#xD;
             CD19 counts within the normal range at screening.&#xD;
&#xD;
          7. Use of immunosuppressants (such as cyclophosphamide, vincristine) other than permitted&#xD;
             oral immunosuppressants within 6 months before first dosing.&#xD;
&#xD;
          8. Has been diagnosed with myelodysplastic syndrome.&#xD;
&#xD;
          9. Has received a live vaccine within 4 weeks before screening or has any live vaccine&#xD;
             planned during the study.&#xD;
&#xD;
        10 Has had an opportunistic infection ≤12 weeks before initial study dosing or is currently&#xD;
        undergoing treatment for a chronic opportunistic infection, such as tuberculosis (TB),&#xD;
        pneumocystis pneumonia, cytomegalovirus, herpes simplex virus, herpes zoster, or atypical&#xD;
        mycobacteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Contact</last_name>
    <phone>+1-877-825-3327</phone>
    <email>medinfoUS@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Clinical Research Center - Hunt - PPDS</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bleeding and Clotting Disorders Institute</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leo W. Jenkins Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment - Dr. Georgi Stranski EAD</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Mulitiprofile Hospital for Active Treatment Sveti Georgi EAD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Merkur</name>
      <address>
        <city>Zagreb</city>
        <state>Grad Zagreb</state>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centre Osijek</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinicki bolnicki centar Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Kurfurstendamm</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>OnkoNet Marburg GmbH</name>
      <address>
        <city>Marburg</city>
        <zip>35037</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rotkreuzklinikum Munchen</name>
      <address>
        <city>Munchen</city>
        <zip>80634</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O.U. Maggiore della Carita</name>
      <address>
        <city>Novara</city>
        <state>Piemonte</state>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Rilievo Nazionale E Di Alta Specializzazione Garibaldi</name>
      <address>
        <city>Catania</city>
        <zip>95122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI)</name>
      <address>
        <city>Trieste</city>
        <zip>34125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univerzitetni klinicni Center Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinical Centre Maribor</name>
      <address>
        <city>Maribor</city>
        <zip>2000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Communal Non-profit Enterprise City Clinical Hospital #4 of Dnipro City Council - PPDS</name>
      <address>
        <city>Dnipropetrovsk</city>
        <state>Dnipropetrovs'ka Oblast'</state>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise Mykolayiv Regional Clinical Hospital the Mykolayiv Regional Council</name>
      <address>
        <city>Mykolaiv</city>
        <state>Mykolaivs'ka Oblast</state>
        <zip>54058</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Municipal Non-Profit Institution Regional Clinical Hospital n a O F Herbachevskyi of Zhytomyr Region</name>
      <address>
        <city>Zhytomyr</city>
        <state>Zhytomyrs'ka Oblast</state>
        <zip>10002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CNE Kyiv City Clinical Hospital #9 EB OF THE KYIV City Council (Kyiv City SA)</name>
      <address>
        <city>Kyiv</city>
        <zip>04112</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center OK!Clinic+of LLC International Institute of Clinical Research</name>
      <address>
        <city>Kyiv</city>
        <zip>2091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Slovenia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 19, 2020</study_first_submitted>
  <study_first_submitted_qc>February 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

